We studied the metabolic anatomy of typical Parkinson's disease (PD) using [18F]fluorodeoxyglucose (FDG) and [18F]fluorodopa (FDOPA) and positron emission tomography (PET). Fourteen PD patients (mean age 49 years) had FDG/PET scans, of which 11 were scanned with both FDOPA and FDG. After the injection of FDOPA, brain uptake and arterial plasma radioactivity were monitored for 2 h. Striatal FDOPA uptake was analyzed with regard to a two-compartment model, and target-to-background ratios (TBRs) and TBR-versus-time slopes were also calculated. Regional patterns of metabolic covariation were extracted from FDG/PET data using the Scaled Subprofile Model (SSM). SSM pattern weights, FDOPA uptake constants (Ki), TBRs, and TBR slopes were correlated with clinical measures for bradykinesia, rigidity, tremor, gait disturbance, left-right asymmetry, dementia, and overall disease severity. In PD patients, rate constants for FDOPA uptake correlated with individual measures of bradykinesia (p = 0.001) and gait disability (p less than 0.05). SSM analysis revealed a distinct pattern of regional metabolic asymmetries, which correlated with motor asymmetries (p less than 0.001) and left-right differences in Ki (p less than 0.01). Our data suggest that in PD patients, FDG/PET and FDOPA/PET may provide unique and complementary information about underlying disease processes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mds.870050304 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deciphering F-DOPA uptake in SDH-related head and neck paragangliomas: a radiomics approach.
J Endocrinol Invest
December 2024
Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University Hospitals, Strasbourg University, Strasbourg, France.
Purpose: To investigate the influence of germline succinate dehydrogenase (SDHx) pathogenic variants on 6-[F]-fluoro-3,4-dihydroxyphenylalanine (F-DOPA) Positron Emission Tomography (PET) radiomic signature of head and neck paragangliomas (HNPGLs).
Methods: Forty-seven patients (20 SDH pathogenic variants carriers) harboring 55 HNPGLs were retrospectively included. HNPGLs were delineated using Nestle adaptive threshold.
A New Tool for Extracting Static and Dynamic Parameters from [F]F-DOPA PET/CT in Pediatric Gliomas.
J Clin Med
October 2024
Department of Informatics, Bioengineering, Robotics and System Engineering (DIBRIS), University of Genoa, 16145 Genoa, Italy.
Article Synopsis
- PET imaging with [F]F-DOPA shows promise for assessing pediatric brain gliomas, but manual extraction of data is slow and inconsistent.
- A new semi-automated Python framework was developed to streamline the processing of PET images and improve efficiency and accuracy in calculating clinical scores.
- The study found that this new method significantly improved reproducibility in extracting important tumor metrics and reduced the variability associated with human input.
Imaging Glucose Metabolism and Dopaminergic Dysfunction in Sheep () Brain Using Positron Emission Tomography Imaging Reveals Abnormalities in OVT73 Huntington's Disease Sheep.
ACS Chem Neurosci
November 2024
Preclinical, Imaging, and Research Laboratories (PIRL), South Australian Health and Medical Research Institute (SAHMRI), Gilles Plains, Adelaide 5086, Australia.
Article Synopsis
- Huntington's disease (HD) is a progressive neurodegenerative condition leading to cognitive, movement, and behavioral issues, ultimately causing disability and death.
- This study evaluates the effectiveness of a transgenic sheep model (OVT73) for PET imaging to track brain metabolism and dysfunction related to HD.
- Findings reveal that younger HD sheep show increased glucose uptake in specific brain regions compared to healthy controls, while both older HD sheep displayed reduced dopamine binding potential, highlighting the potential of this model for studying HD progression.
Update on the Role of [F]FDOPA PET/CT.
Semin Nucl Med
November 2024
Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
[F]-dihydroxyphenylalanine ([F]FDOPA) is a radiopharmaceutical used in a broad spectrum of diseases, including neuroendocrine tumors (NETs), congenital hyperinsulinism, parkinsonian syndromes and neuro-oncology. Genetic analysis and disease specific biomarkers may guide the optimum selection of patients that may benefit most from [F]FDOPA PET in different stages of several neuroendocrine neoplasms and in congenital hyperinsulinism. For clinical routine in neuro-oncology, indications for [F]FDOPA PET include tumor delineation and distinguishing between treatment related changes and recurrent disease.
View Article and Find Full Text PDFImaging Role in Diagnosis, Prognosis, and Treatment Response Prediction Associated with High-grade Glioma.
J Med Signals Sens
March 2024
Department of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: Glioma is one of the most drug and radiation-resistant tumors. Gliomas suffer from inter- and intratumor heterogeneity which makes the outcome of similar treatment protocols vary from patient to patient. This article is aimed to overview the potential imaging markers for individual diagnosis, prognosis, and treatment response prediction in malignant glioma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!